Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
BMC Fam Pract ; 19(1): 58, 2018 05 09.
Artículo en Inglés | MEDLINE | ID: mdl-29743033

RESUMEN

BACKGROUND: Evidence-based preventive care recommendations have been well established, but studies have persistently reported gaps between these recommendations and general practitioners' practices in providing preventive care. Many studies have explored factors that affect the delivery of preventive care from the perspectives of the practitioners, but relatively few have evaluated the patients' point of view. The purpose of this study was to explore patients' understanding of preventive care, the actions they were taking in terms of preventive health and their expectations from family doctors in providing preventive care. METHODS: A qualitative study was conducted based on one-on-one in-depth interviews. Twenty-eight patients without chronic illnesses were purposively recruited from government general outpatient clinics in Hong Kong. The interviews took place between November 2013 and February 2014. RESULTS: The participants' knowledge of preventive care was limited, and their preventive practices were mostly restricted to healthy lifestyle practices. They rarely obtained individualised preventive care advice from doctors. Screening investigations were initiated after symptoms had already occurred, and the decision of what to check was arbitrary. Few of the participants knew what they wanted from their doctors in terms of preventive care. CONCLUSIONS: These findings show significant gaps between evidence-based preventive recommendations and patients' current knowledge and practice, and show the need for a wider spectrum of preventive care education and reliable sources to provide individualised and affordable preventive assessment and screening services. Most importantly, primary care providers must take a more proactive role to provide preventive services.


Asunto(s)
Instituciones de Atención Ambulatoria , Conocimientos, Actitudes y Práctica en Salud , Servicios Preventivos de Salud , Adulto , Anciano , Práctica Clínica Basada en la Evidencia , Hong Kong , Humanos , Entrevistas como Asunto , Persona de Mediana Edad , Instalaciones Públicas , Investigación Cualitativa , Adulto Joven
2.
J Clin Invest ; 121(10): 4003-14, 2011 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-21881206

RESUMEN

Sepsis-associated acute kidney injury (AKI) is a common and morbid condition that is distinguishable from typical ischemic renal injury by its paucity of tubular cell death. The mechanisms underlying renal dysfunction in individuals with sepsis-associated AKI are therefore less clear. Here we have shown that endotoxemia reduces oxygen delivery to the kidney, without changing tissue oxygen levels, suggesting reduced oxygen consumption by the kidney cells. Tubular mitochondria were swollen, and their function was impaired. Expression profiling showed that oxidative phosphorylation genes were selectively suppressed during sepsis-associated AKI and reactivated when global function was normalized. PPARγ coactivator-1α (PGC-1α), a major regulator of mitochondrial biogenesis and metabolism, not only followed this pattern but was proportionally suppressed with the degree of renal impairment. Furthermore, tubular cells had reduced PGC-1α expression and oxygen consumption in response to TNF-α; however, excess PGC-1α reversed the latter effect. Both global and tubule-specific PGC-1α-knockout mice had normal basal renal function but suffered persistent injury following endotoxemia. Our results demonstrate what we believe to be a novel mechanism for sepsis-associated AKI and suggest that PGC-1α induction may be necessary for recovery from this disorder, identifying a potential new target for future therapeutic studies.


Asunto(s)
Lesión Renal Aguda/fisiopatología , Inflamación/fisiopatología , Transactivadores/fisiología , Lesión Renal Aguda/inducido químicamente , Lesión Renal Aguda/genética , Lesión Renal Aguda/patología , Animales , Modelos Animales de Enfermedad , Endotoxemia/genética , Endotoxemia/patología , Endotoxemia/fisiopatología , Inflamación/inducido químicamente , Túbulos Renales Proximales/patología , Túbulos Renales Proximales/fisiopatología , Lipopolisacáridos/toxicidad , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Mitocondrias/fisiología , Coactivador 1-alfa del Receptor Activado por Proliferadores de Peroxisomas gamma , Sepsis/inducido químicamente , Sepsis/genética , Sepsis/fisiopatología , Transactivadores/deficiencia , Transactivadores/genética , Factores de Transcripción , Transcriptoma
3.
Am J Hematol ; 81(6): 443-7, 2006 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-16680745

RESUMEN

Pulmonary hypertension is a common complication of beta-thalassemia major. We report a case of successful treatment of pulmonary hypertension in a patient with beta-thalassemia major and review the literature on pulmonary hypertension and beta-thalassemia major. A 28-year-old man with beta-thalassemia major, splenectomy, hepatitis C, and hemosiderosis who presented with increasing dyspnea on exertion was diagnosed with pulmonary hypertension. After receiving continuous epoprostenol infusion and desferoxamine, his functional capacity and hemodynamic status improved. To our knowledge, this is the first case of pulmonary hypertension associated with beta-thalassemia treated with continuous epoprostenol infusion and desferoxamine. Epoprostenol, beneficial in the treatment of other types of pulmonary hypertension, may ameliorate the morbidity and mortality of pulmonary hypertension associated with thalassemia.


Asunto(s)
Antihipertensivos/administración & dosificación , Deferoxamina/administración & dosificación , Epoprostenol/administración & dosificación , Hipertensión Pulmonar/tratamiento farmacológico , Sideróforos/administración & dosificación , Talasemia beta/tratamiento farmacológico , Adulto , Disnea/complicaciones , Disnea/tratamiento farmacológico , Hemosiderosis/complicaciones , Hemosiderosis/tratamiento farmacológico , Hepatitis C/complicaciones , Hepatitis C/tratamiento farmacológico , Humanos , Hipertensión Pulmonar/complicaciones , Hipertensión Pulmonar/diagnóstico , Masculino , Recuperación de la Función/efectos de los fármacos , Inducción de Remisión , Talasemia beta/complicaciones
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...